ARV-393

Arvinas Inc. · Phase 1 active Small molecule

At a glance

Generic name	ARV-393
Sponsor	Arvinas Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma. (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ARV-393 CI brief — competitive landscape report
ARV-393 updates RSS · CI watch RSS
Arvinas Inc. portfolio CI